Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein

doi:10.4254/wjh.v7.i11.1553

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 11

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16250)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

1015

WORD

372

HTML

10274

Figures (1-1)

555

Tables (1-2)

481

Sum=12697

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1425

Download

2123

Sum=3548

Jun 18, 2015 (publication date) through Mar 9, 2026

Times Cited of This Article

Times Cited (33)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Hepatol. Jun 18, 2015; 7(11): 1553-1561
Published online Jun 18, 2015. doi: 10.4254/wjh.v7.i11.1553

Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein

Su Jong Yu, Yoon Jun Kim

Su Jong Yu, Yoon Jun Kim, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 110-744, South Korea

Author contributions: Kim YJ designed research; Yu SJ performed literature search and wrote the paper.

Conflict-of-interest: The authors have no commercial, proprietary or financial interest in the products or companies described in this article.

Correspondence to: Yoon Jun Kim, MD, Professor, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, South Korea. yoonjun@snu.ac.kr

Telephone: +82-2-20723081 Fax: +82-2-7436701

Received: September 23, 2014
Peer-review started: September 23, 2014
First decision: November 27, 2014
Revised: March 16, 2015
Accepted: April 10, 2015
Article in press: April 14, 2015
Published online: June 18, 2015
Processing time: 265 Days and 19.9 Hours

Core Tip

Core tip: Given the modest survival gain and the limitation of sorafenib, such as resistance and tolerability, there are still clinical unmet needs in the management of patients with hepatocellular carcinoma (HCC) accompanying portal vein tumor thrombosis (PVTT). Surgical resection-based multimodal treatments including liver transplantation and transarterial chemoembolization-based appropriate combination strategies for resectable HCC accompanying PVTT may improve overall survival in these patients.